VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sardar Biglari Sells 1,211 Shares of Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock in a transaction on Tuesday, July 14th. The stock was sold at an average price of $16.73, for a total value of $20,260.03. Following the transaction, the insider owned 3,559,243 shares in the company, valued at approximately $59,546,135.39. This represents a 0.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30.
• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43.

VanEck Biotech ETF Stock Performance

VanEck Biotech ETF stock opened at $206.25 on Friday. The company has a 50-day moving average price of $192.67 and a 200 day moving average price of $191.86. VanEck Biotech ETF has a 12-month low of $154.75 and a 12-month high of $212.54.

Institutional Trading of VanEck Biotech ETF

Hedge funds and other institutional investors have recently made changes to their positions in the company. Empowered Funds LLC purchased a new stake in shares of VanEck Biotech ETF during the 4th quarter valued at approximately $38,000. Flagship Harbor Advisors LLC purchased a new position in VanEck Biotech ETF in the fourth quarter worth approximately $47,000. Allworth Financial LP increased its stake in VanEck Biotech ETF by 255.0% during the fourth quarter. Allworth Financial LP now owns 426 shares of the company’s stock worth $81,000 after acquiring an additional 306 shares during the last quarter. Fifth Third Bancorp acquired a new stake in VanEck Biotech ETF during the first quarter worth $127,000. Finally, Huntington National Bank purchased a new stake in VanEck Biotech ETF in the fourth quarter valued at $132,000. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.